Lario Therapeutics awarded $6M Grant from The Michael J. Fox Foundation for Parkinson’s Research

Award supports preclinical research of Lario’s CaV2.3 calcium channel inhibitors as a novel disease-modifying approach for treatment of Parkinson’s disease.